BioCentury | Nov 18, 2020
Product Development
Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac
...known adverse events for the class.BioMarin, Deep Genomics enter oligonucleotide dealBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will use Deep Genomics Inc.’s...
...rare disease indiccations; financial terms are undisclosed. BioMarin will receive an exclusive option to obtain Deep Genomics’...
...rare disease indiccations; financial terms are undisclosed. BioMarin will receive an exclusive option to obtain Deep Genomics’...